Cargando…

Antibacterial Drug Development: A New Approach Is Needed for the Field to Survive and Thrive

It is often said that the marketplace for new antibiotics is broken. This notion is supported by the observation that many recently-approved antibiotics to treat drug-resistant bacteria have failed commercially in a spectacular fashion. Today, companies with peak market-cap values in excess of USD 5...

Descripción completa

Detalles Bibliográficos
Autores principales:	Safir, M. Courtney, Bhavnani, Sujata M., Slover, Christine M., Ambrose, Paul G., Rubino, Christopher M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2020
Materias:	Communication
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7400211/ https://www.ncbi.nlm.nih.gov/pubmed/32679767 http://dx.doi.org/10.3390/antibiotics9070412

Ejemplares similares

593. Population Pharmacokinetic Model Development for Epetraborole and Mycobacterium avium Complex (MAC) Lung Disease Patients Using Data from Phase 1 and 2 Studies
por: Ganesan, Harish, et al.
Publicado: (2022)

Population Pharmacokinetic Analyses for Omadacycline Using Phase 1 and 3 Data
por: Lakota, Elizabeth A., et al.
Publicado: (2020)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

A Broken Antibiotic Market: Review of Strategies to Incentivize Drug Development
por: Bhavnani, Sujata M, et al.
Publicado: (2020)

Population Pharmacokinetic Analyses for Tebipenem after Oral Administration of Pro-Drug Tebipenem Pivoxil Hydrobromide
por: Ganesan, H., et al.
Publicado: (2023)

LB2306. Population Pharmacokinetic (PPK), Pharmacokinetic/Pharmacodynamic attainment (PTA), and Clinical Pharmacokinetic/Pharmacodynamic (PK/PD) Analyses for Sulbactam-Durlobactam (SUL-DUR) to Support Dose Selection for the Treatment of Acinetobacter baumannii-calcoaceticus Complex (ABC) Infections
por: Bhavnani, Sujata M, et al.
Publicado: (2022)

Time for Precision: A World Without Susceptibility Breakpoints
por: Bader, Justin C, et al.
Publicado: (2018)

Prediction of lefamulin epithelial lining fluid penetration after intravenous and oral administration using Phase 1 data and population pharmacokinetics methods
por: Zhang, Li, et al.
Publicado: (2019)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

1417. Evaluating the Dissonance Between C(max) and AUC with Clinically Utilized Aminoglycoside (AG) Dosing Regimens: Use of Tobramycin (TOB) Against Pseudomonas aeruginosa (PA) as a Case Study
por: Onufrak, Nikolas J, et al.
Publicado: (2018)

Surviving and thriving after breast cancer treatment
por: Saunders, Christobel M, et al.
Publicado: (2022)

1105. Population Pharmacokinetic Analyses for Tebipenem After the Administration of Tebipenem Pivoxil Hydrobromide
por: Ganesan, Harish, et al.
Publicado: (2021)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

At the Crossroads of Stewardship and Technology: Impact of Pharmacokinetic-Pharmacodynamic (PK-PD) Integrated Electronic Decision Support Software (EDSS) on the Treatment of Patients Infected with Pneumonia
por: Bader, Justin C, et al.
Publicado: (2017)

228. Epidemiology and Susceptibility Profiles of ST131-O25b Escherichia coli Detected Among Cephalosporin and/or Carbapenem-Resistant Isolates Collected in United States Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

Phytomelatonin: Assisting Plants to Survive and Thrive
por: Reiter, Russel J., et al.
Publicado: (2015)

Population Pharmacokinetic Analyses for Plazomicin Using Pooled Data from Phase 1, 2, and 3 Clinical Studies
por: Trang, Michael, et al.
Publicado: (2019)

1304. Characterization of Tebipenem Pivoxil Hydrobromide Pharmacokinetics-Pharmacodynamics (PK-PD) in a Neutropenic Murine Acute Pyelonephritis (AP) Model
por: VanScoy, Brian D, et al.
Publicado: (2020)

Nutritional approach to failure to thrive
por: Jeong, Su Jin
Publicado: (2011)

THRIVING OR SURVIVING? FACTORS ASSOCIATED WITH NURSING HOME SOCIAL SERVICE DIRECTORS REPORTING THRIVING AT WORK
por: Kusmaul, Nancy, et al.
Publicado: (2022)

Think and grow digital: what the net generation needs to know to survive and thrive in any organization
por: Merks-Benjaminsen, Joris
Publicado: (2015)

From surviving to thriving: What evidence is needed to move early child-development interventions to scale?
por: Tomlinson, Mark
Publicado: (2018)

Getting it Right the First Time: Relating Pharmacokinetic-Pharmacodynamic Target Attainment and Patient Outcomes
por: Bulik, Catharine C, et al.
Publicado: (2017)

Liars and outliers: enabling the trust that society needs to thrive
por: Schneier, Bruce
Publicado: (2012)

Resilience after trauma: from surviving to thriving
por: Nugent, Nicole R., et al.
Publicado: (2014)

Survive or thrive: tradeoff strategy for cellular senescence
por: Park, Sang Chul
Publicado: (2017)

Impact Factor is Off the Ventilator: Survives and is Thriving
por: Jawaid, Shaukat Ali, et al.
Publicado: (2018)

Thrive or survive: prokaryotic life in hypersaline soils
por: Vera-Gargallo, Blanca, et al.
Publicado: (2023)

Survive or thrive after ICU: what’s the score?
por: McNicholas, Bairbre A., et al.
Publicado: (2023)

Pharmacokinetic/pharmacodynamic target attainment analyses to support intravenous and oral lefamulin dose selection for the treatment of patients with community-acquired bacterial pneumonia
por: Bhavnani, Sujata M, et al.
Publicado: (2019)

2568. Characterization of Sulopenem Pharmacokinetics-Pharmacodynamics Using a One-Compartment In Vitro Infection Model
por: VanScoy, Brian D, et al.
Publicado: (2023)

Failure of siblings to thrive beyond 5 years of age
por: Jain, Himanshu, et al.
Publicado: (2013)

What do photosynthetic organisms need to thrive in all circumstances?
por: Moulin, Solène L Y
Publicado: (2023)

2549. Pharmacometric Analyses to Support Sulbactam-Durlobactam (SUL-DUR) Dosing Regimens in Patients with Altered Renal Function
por: Larson, Kajal, et al.
Publicado: (2023)

Startup life: surviving and thriving in a relationship with an entrepreneur
por: Feld, Brad, et al.
Publicado: (2013)

Managing Uncertainty: Strategies for Surviving and Thriving in Turbulent Times
por: Syrett, Michel
Publicado: (2012)

The nomadic developer: surviving and thriving in the world of technology consulting
por: Erickson, Aaron
Publicado: (2009)

Correction: Thrive or survive: prokaryotic life in hypersaline soils
por: Vera-Gargallo, Blanca, et al.
Publicado: (2023)

Pharmacological Basis of CD101 Efficacy: Exposure Shape Matters
por: Lakota, Elizabeth A., et al.
Publicado: (2017)

1392. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Inhaled ME1100 Dose Selection
por: Bhavnani, Sujata M, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_mvmb42ove6q9jq6grl7al9lde0